Family clinical case report of a MYBPC3 gene sequence variant with diverse phenotypic expressions

In recent years, the results of numerous scientific studies have shifted the focus from phenotypic traits to genotype as the basis for the modern classification of primary cardiomyopathies (CMP). An example of this genotype-specific approach is CMP associated with variants in the MYBPC3 gene, which holds significant clinical relevance. One feature of this heart disease is significant phenotypic heterogeneity. Furthermore, there is high variability in the disease penetrance and expressivity, even among patients with the same MYBPC3 gene variant, which complicates risk stratification, prognosis determination and the personalization of therapeutic approach. This article presents a case of a family with a likely pathogenic MYBPC3 gene variant (rs727503195, c.1790G>A, p.Arg597Gln) in three generations. The described family case clearly demonstrates the significant heterogeneity in the CMP clinical and morphological characteristics associated with MYBPC3 gene variants.

1. Wang Y, Jia H, Song J. Accurate Classification of Non-ischemic Cardiomyopathy. Curr Cardiol Rep. 2023;25(10):1299-317. DOI:10.1007/s11886-023-01944-0.

2. Myasnikov RP, Kuzina NN, Nefedova DA, et al. Desmoplakin and features of desmoplakin cardiomyopathy. Russian Journal of Cardiology. 2023;28(11):5648 (In Russ.)

3. Tudurachi BS, Zăvoi A, Leonte A, et al. An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy. Int J Mol Sci. 2023;24(13):10510. DOI:10.3390/ijms241310510.

4. Helms AS, Thompson AD, Glazier AA, et al. Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. Circ Genom Precis Med. 2020;13(5):396-405. DOI:10.1161/CIRCGEN.120.002929.

5. Toepfer CN, Wakimoto H, Garfinkel AC, et al. Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin. Sci Transl Med. 2019;11(476):eaat1199. DOI:10.1126/scitranslmed.aat1199.

6. Helms AS, Tang VT, O’Leary TS, et al. Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy. JCI Insight. 2020;5(2):e133782. DOI:10.1172/jci.insight.133782.

7. Zou X, Ouyang H, Lin F, et al. MYBPC3 deficiency in cardiac fibroblasts drives their activation and contributes to fibrosis. Cell Death Dis. 2022;13(11):948. DOI:10.1038/s41419-022-05403-6.

8. Ananthamohan K, Stelzer JE, Sadayappan S. Hypertrophic cardiomyopathy in MYBPC3 carriers in aging. J Cardiovasc Aging. 2024;4(1):9. DOI:10.20517/jca.2023.29.

9. Marian AJ. Molecular Genetic Basis of Hypertrophic Cardiomyopathy. Circ Res. 2021;128(10):1533-53. DOI:10.1161/CIRCRESAHA.121.318346.

10. Velicki L, Jakovljevic DG, Preveden A, et al. Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy. BMC Cardiovasc Disord. 2020;20(1):516. DOI:10.1186/s12872-020-01807-4.

11. Jordan E, Peterson L, Ai T, et al. Evidence-Based Assessment of Genes in Dilated Cardiomyopathy. Circulation. 2021;144(1):7-19. DOI:10.1161/CIRCULATIONAHA.120.053033.

12. Sheridan C. Genetic medicines aim straight for the heart. Nat Biotechnol. 2023;41(4):435-7. DOI:10.1038/s41587-023-01745-4.

13. Myasnikov RP, Kulikova AV, Meshkov AN, et al. The combination of left ventricular non-compaction and hypertrophic cardiomyopathy in one family with a pathogenic variant in the MYBPC3 gene (rs397516037). Russian Journal of Cardiology. 2020;25(10):4115 (In Russ.) Мясников Р.П., Куликова О.В., Мешков А.Н. и др. Сочетание некомпактного миокарда левого желудочка и гипертрофической кардиомиопатии в одной семье с патогенным вариантом нуклеотидной последовательности в гене MYBPC3 (rs397516037). Российский кардиологический журнал. 2020;25(10):4115]. DOI:10.15829/1560-4071-2020-4115.

14. Vodnjov N, Maver A, Teran N, et al. Clinical Outcome of Hypertrophic Cardiomyopathy in Probands with the Founder Variant c.913_914del in MYBPC3: A Slovenian Cohort Study. J Cardiovasc Transl Res. 2025;18(1):110-20. DOI:10.1007/s12265-024-10551-5.

15. Meshkov AN, Myasnikov RP, Kiseleva AV, et al. Genetic landscape in Russian patients with familial left ventricular noncompaction. Front Cardiovasc Med. 2023;10:1205787. DOI:10.3389/fcvm.2023.1205787.

16. Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(4):372-89. DOI:10.1016/j.jacc.2021.12.002.

17. Nefedova DA, Myasnikov RP, Kulikova OV, et al. MYBPC3-associated cardiomyopathy: features of the course and prospects for specific therapy. Cardiovascular Therapy and Prevention. 2024;23(12):4257 (In Russ.)

18. Adalsteinsdottir B, Burke M, Maron BJ, et al. Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers. Open Heart. 2020;7(1):e001220. DOI:10.1136/openhrt-2019-001220.

19. Fabiani M, Micolonghi C, Caroselli S, et al. MYBPC3 c.2309-2A>G: exploring a founder variant in Italian hypertrophic cardiomyopathy patients. Eur J Hum Genet. 2025. DOI:10.1038/s41431-025-01873-2.

20. Glazier AA, Thompson A, Day SM. Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy. Pflugers Arch. 2019;471(5):781-93. DOI:10.1007/s00424-018-2226-9.

21. Carrier L. Targeting the population for gene therapy with MYBPC3. J Mol Cell Cardiol. 2021;150:101-8. DOI:10.1016/j.yjmcc.2020.10.003.